Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

NCT05760612 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Early-stage Breast Cancer
HER2-positive Breast Cancer
Adjuvant Treatment After Trastuzumab
RCB Classification 1-2
Neratini

Interventions

DRUG: Trastuzumab and neratinib
DRUG: Trastuzumab and Pertuzumab

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University